Nebenwirkungen · Capecitabine Teva
Capecitabine Teva 150 mg film-coated tablets Capecitabine Teva 500 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 19
HOS-215449 · Präparat HOS-155434
An analysis of safety data in patients ≥60 years of age treated with capecitabine monotherapy and an analysis of patients treated with capecitabine plus docetaxel combination therapy showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions and treatment-related serious adverse reactions compared to patients <60 years of age. Patients ≥60 years of age treated with capecitabine plus docetaxel also had more early withdrawals from treatment due to adverse reactions compared to patients <60 years of age.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T15:40:00Z · SHA-256 360b33238effee7033c9ecfa3731a36e172b67d4837e971f09a6e80d5cda73df · Passage 7ad330efd4e3a3b955d03ab1c045e0a8dd30186e05f9d12bd5d5056c0c91f4aa · Zeichen 27034–27570 im Abschnitt